

Attorney Docket No. 070478
Application No. 10/693,025

Proposed Claims

1. (Proposed) A method for amplifying a signal of RNA expression analysis using a flow-cytometer for detection of a polynucleotide, comprising the steps of

(a) providing at least one a plurality of identifiable, fluorescent detectable microspheres comprising at least two spectrally distinct fluorochromes; wherein the microspheres are coupled with at least one at least one pre-optimized oligonucleotide having sequence complementary to an RNA target polynucleotide;

(b) hybridizing a labeled target polynucleotide to said oligonucleotide to form an oligonucleotide/target polynucleotide complex, wherein said complex comprises a detectable signal through the binding of a receptor to the label;

(c) providing a labeled ligand for said receptor, wherein when said ligand binds said receptor, said signal is amplified; and

(d) identifying said microsphere and quantifying the amplified labeled ligand signal via flow cytometry.

2. (Original) The method of claim 1, wherein the pre-optimized oligonucleotide is selected with an algorithm.

3. (Original) The method of claim 2, wherein said algorithm utilizes at least one of the following selection criteria:

(a) selecting at least one perfect match pre-optimized oligonucleotide, wherein the selected at least one perfect match pre-optimized oligonucleotide has an acceptable measure of correlation with a standard gene expression value;

#1874367

Attorney Docket No. 070478
Application No. 10/693,025

- (b) selecting at least one perfect match and minus mismatch pre-optimized oligonucleotide pair, wherein within a pair the selected at least one perfect match pre-optimized oligonucleotide minus the mismatch pre-optimized oligonucleotide has an acceptable measure of correlation with a standard gene expression value;
- (c) selecting at least one pair of pre-optimized oligonucleotides from different pre-optimized oligonucleotide sets, wherein the ratio of signals in the pre-optimized oligonucleotides in the at least one pair of pre-optimized oligonucleotides has an acceptable correlation with a standard signal ratio; and
- (d) selecting at least one perfect match pre-optimized oligonucleotide, wherein the perfect match pre-optimized oligonucleotide has an acceptable relative standard deviation.

4. (Original) The method of claim 1, wherein said pre-optimized oligonucleotide is further defined as being selected by the steps of

providing a sample comprising at least one target polynucleotide; subjecting said sample to an array of oligonucleotides, wherein the hybridization of said target polynucleotide to at least one oligonucleotide in the array provides a detectable hybridization fingerprint; and identifying at least one optimal oligonucleotide from said fingerprint.

5. (Original) The method of claim 1, wherein said pre-optimized oligonucleotide is further defined as being selected by the steps of:

providing a sample comprising a plurality of target polynucleotides, said target polynucleotides defined as RNA polynucleotides from more than one gene; subjecting said sample to an array of oligonucleotides, wherein the hybridization of

more than one different RNA polynucleotide to a respective oligonucleotide in the array provides a detectable hybridization fingerprint for more than one gene; and identifying at least one optimal oligonucleotide for said more than one gene from said fingerprint.

6. (Original) The method of claim 1, wherein said identifying step utilizes an algorithm to identify said oligonucleotide.

#1874367

Attorney Docket No. 070478
Application No. 10/693,025

7. (Original) The method of claim 6, wherein said algorithm identifies an oligonucleotide having complete complementarity to at least a portion of said target polynucleotide.
8. (Original) The method of claim 1, wherein the target polynucleotide is ~~comprised included~~ in a plurality of RNA polynucleotides and the concentration of said plurality is from about 1 μ g to about 10 μ g.
9. (Original) The method of claim 1, wherein said ligand comprises an antibody.
10. (Original) The method of claim 1, wherein the label of the target polynucleotide and/or the label of the ligand comprises a fluorescent label, an enzyme label, a chemical label, or a gold label.
11. (Original) The method of claim 1, wherein the label of the target polynucleotide and the label of the ligand are identical.
12. (Proposed) The method of claim 1, wherein said ~~identifiable, fluorescent-detectable microsphere is comprised in a~~ plurality of ~~identifiable, fluorescent-detectable~~ microspheres and ~~said target polynucleotide is comprised in~~ hybridizes with a plurality of RNA target polynucleotides.
13. (Proposed) The method of claim 12, wherein the plurality of RNA target polynucleotides is comprised in an mRNA-containing sample, and said method is further defined as a method for providing mRNA expression profiling information.
14. (Original) The method of claim 12, wherein at least one microsphere in said plurality of microspheres comprises different oligonucleotides from the oligonucleotides of another microsphere in said plurality.
15. (Proposed) The method of claim 12, wherein at least one ~~identifiable fluorescent-detectable~~ microsphere in the plurality comprises more than one nonidentical pre-optimized oligonucleotide having sequence complementary to the same RNA polynucleotide.
16. (Proposed) A composition, comprising:

#1874367

Attorney Docket No. 070478
Application No. 10/693,025

a plurality of identifiable, fluorescent detectable microspheres comprising at least two spectrally distinct fluorochromes; wherein the microspheres are, each identifiable fluorescent detectable microsphere-linked to at least one pre-optimized oligonucleotide, wherein said oligonucleotide is hybridized to a labeled RNA polynucleotide forming an oligonucleotide/labeled RNA polynucleotide hybridized complex, and wherein said complex comprises a detectable signal through the binding of a receptor to the label, and said signal is amplified upon binding of a labeled ligand for the receptor; and identifying said microspheres and quantifying the amplified labeled ligand signal via flow cytometry.

17. (Proposed) The composition of claim 16, wherein at least one identifiable, fluorescent detectable microsphere in said plurality of identifiable, fluorescent detectable microspheres comprises different oligonucleotides from the oligonucleotides of another identifiable, fluorescent detectable microsphere in said plurality.

18. (Proposed) The composition of claim 16, wherein at least one identifiable, fluorescent detectable microsphere in the plurality comprises more than one non-identical pre-optimized oligonucleotide each having sequence complementary to the same RNA polynucleotide.

19. (Withdrawn) A method of optimizing an oligonucleotide hybridization-based assay, comprising the steps of:

providing a sample comprising at least one target polynucleotide; subjecting said sample to an array of oligonucleotides, wherein the hybridization of said target polynucleotide to at least one oligonucleotide in the array provides a detectable hybridization fingerprint;

identifying at least one optimal oligonucleotide from said fingerprint, wherein said identifying step utilizes an algorithm defined by at least one of the following selection criteria:

- (a) selecting at least one perfect match pre-optimized oligonucleotide, wherein the selected at least one perfect match pre-optimized oligonucleotide has an acceptable measure of correlation with a standard gene expression value;
- (b) selecting at least one perfect match and minus mismatch pre-optimized oligonucleotide pair, wherein within a pair the selected at least one perfect match pre-

#1874367

Attorney Docket No. 070478
Application No. 10/693,025

optimized oligonucleotide minus the mismatch pre-optimized oligonucleotide has an acceptable measure of correlation with a standard gene expression value';

- (c) selecting at least one pair of pre-optimized oligonucleotides from different pre-optimized oligonucleotide sets, wherein the ratio of signals in the pre- optimized oligonucleotides in the at least one pair of pre-optimized oligonucleotides has an acceptable correlation with a standard signal ratio; and
- (d) selecting at least one perfect match pre-optimized oligonucleotide, wherein the perfect match pre-optimized oligonucleotide has an acceptable relative standard deviation; and subjecting said optimal oligonucleotide to an oligonucleotide hybridization-based assay.

#1874367